Tempest Therapeutics: Funding, Investors & Team (Sep 2026)
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.
Tempest Therapeutics has raised $19.0M across 3 funding rounds on record, the most recent an undisclosed round of $2.0M announced in May 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Tempest Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2026.
Tempest Therapeutics Funding Rounds
Tempest Therapeutics raised $15.0M in a Post-IPO Equity announced in Apr 2022.
3.9 years later, an undisclosed round of $2.0M was announced in Mar 2026.
2 months later, an undisclosed round of $2.0M was announced in May 2026.
Tempest Therapeutics Founders and Leadership Team
Contact details for the Tempest Therapeutics team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Tempest Therapeutics Funding Compared to Other Biotechnology Startups
Tempest Therapeutics' latest round of $2.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Tempest Therapeutics in Biotechnology and San Francisco
Companies Similar to Tempest Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Tempest Therapeutics Funding FAQs
What does Tempest Therapeutics do?
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.
How much funding has Tempest Therapeutics raised?
Tempest Therapeutics has raised $19.0M across 3 rounds on record. The most recent is an undisclosed round of $2.0M announced in May 2026.
When did Tempest Therapeutics last raise funding?
Tempest Therapeutics' most recent funding round on record is an undisclosed round of $2.0M, announced in May 2026.
Who founded Tempest Therapeutics?
FundedIQ lists Matt Angel (Founder) at Tempest Therapeutics.
Who is the CEO of Tempest Therapeutics?
Thomas Dubensky is listed as CEO at Tempest Therapeutics.
Where is Tempest Therapeutics headquartered?
Tempest Therapeutics is based in San Francisco, California, United States.
How many employees does Tempest Therapeutics have?
Tempest Therapeutics is in the 11-50 employee band.
How does Tempest Therapeutics' funding compare to other Biotechnology startups?
Tempest Therapeutics' latest round of $2.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Tempest Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tempest Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.